Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?
Cancer Treat Rev
; 106: 102392, 2022 May.
Article
em En
| MEDLINE
| ID: mdl-35436729
ABSTRACT
Immunotherapy has revolutionized the oncology field during the last years, mainly with the introduction of immune checkpoint inhibitors in the clinical routine. Despite the recent approval of these drugs for the treatment of triple-negative breast cancer, most breast cancer patients cannot benefit from immunotherapy as most tumors are not considered immunoreactive. Therefore, new strategies must be developed to bring immunotherapy closer to breast cancer patients. The introduction of oncolytic viruses in the immuno-oncology field has shown promising results in cancer treatment, including breast cancer. However, a better understanding of their mechanisms of action, increase evidence of safety and efficacy, and the implications of its use as a systemic therapy must be examined in more depth. This review provides a summary of oncolytic virotherapy in the context of breast cancer, both in the pre-clinical and clinical setting.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Contexto em Saúde:
6_ODS3_enfermedades_notrasmisibles
Problema de saúde:
6_breast_cancer
Assunto principal:
Vírus Oncolíticos
/
Terapia Viral Oncolítica
/
Neoplasias de Mama Triplo Negativas
Limite:
Humans
Idioma:
En
Revista:
Cancer Treat Rev
Ano de publicação:
2022
Tipo de documento:
Article